Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

JMP Securities maintained a Market Outperform rating and a $41.00 price target for Exelixis (NASDAQ:EXEL) shares, aligning with the broader analyst consensus as five analysts have recently revised ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...